
Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3
Dovato Recommended in Treatment Guidelines
EACS Guidelines
Dovato is recommended as an initial regimen for treatment naïve patients and as a switch strategy for virologically supressed patients 1
Requirements for treatment naïve patients:
- HBsAg negative
- HIV Viral load <500,000 copies/ml
- CD4 count >200 cells/µL
DHHS Guidelines
Dovato is recommended as an initial regimen for most PLHIV (AI)*+ and as a good option for virologically suppressed patients who have no evidence of resistance to either drug 2
Exclusions for treatment naïve patients:
- HIV viral load of >500,000 copies/ml
- HBV co-infection
- Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available
References:
- European AIDS Clinical Society Guidelines Version 10.0. November 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed April 2020.
- Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 2020.
- DOVATO Summary of Product Characteristics. https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last accessed: June 2020.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trade marks are owned by or licensed to the ViiV Healthcare group of companies.